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Abstract The antioxidant activity of melatonin (MEL) has
been considered to constitute part of its physiological as well as
pharmacological effects. However, as described herein we found
a profound prooxidant activity of micro- to millimolar concen-
trations of MEL in the human leukemic Jurkat cell line. This
prooxidant effect was increased in glutathione-depleted cells and
counteracted by antioxidants. As a consequence MEL promoted
fas-induced cell death. These data therefore indicate that MEL
may be a modulator of the cellular redox status, but does not
necessarily act as an intracellular antioxidant. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
The pineal hormone melatonin (MEL) has been shown to
exhibit distinct antioxidant features in vitro as well as in vivo
(reviewed in [1]). Based on these ¢ndings, MEL was consid-
ered to exert its physiological and pharmacological e¡ects at
least partly via its antioxidant activity [2]. Furthermore, MEL
was suggested to have therapeutic implications in deferring
aging processes [1,2], where reactive oxygen species (ROS)
are known to play an important role [3]. More recently, how-
ever, only a limited antioxidant activity of MEL was observed
in several systems [4^7].
Besides promoting deleterious e¡ects in high concentra-
tions, ROS function as intracellular downstream messengers
targeting speci¢c proteins and genes [8^10]. For example, pro-
grammed cell death in lymphocytes is known to be in£uenced
by alterations of the cellular redox state as well as by intra-
cellular ROS formation [11^16]. Since little is known about
e¡ects of MEL on the intracellular redox state, even though
MEL can easily cross cell membranes due to its amphiphilicity
[17], we examined whether MEL interferes with intracellular
ROS production in fas-induced cell death in Jurkat cells, a
human leukemic T-cell line, which constitutively expresses the
fas receptor [18].
2. Materials and methods
2.1. Drugs and cell cultures
If not otherwise speci¢ed, reagents were purchased from Sigma (St.
Louis, MO, USA) and were of analytical grade or better. The human
leukemic T-cell line Jurkat E6.1 was obtained from the European
Collection of Animal Cell Cultures and cultured in RPMI1640 me-
dium with 10% fetal calf serum (FCS) (both from PAA Laboratories,
Exton, USA), 100 IU/ml penicillin (Biochemie, Vienna, Austria) and
100 Wg/ml streptomycin. For experimental studies, cells were washed
twice in PBS (10 mM sodium phosphate, 160 mM NaCl, pH = 7.4)
and resuspended in RPMI1640 at a concentration of 106 cells/ml,
unless otherwise mentioned. Cell viability as determined with trypan
blue exclusion test and propidium iodide staining and FACS analysis
was s 98%.
MEL was dissolved in ethanol to give a 500 mM stock solution,
which was further diluted in RPMI1640 to give a 1 mM (for one
experimental setup 2.5 mM) concentration resulting in a 0.2% (0.5%
respectively) ethanol concentration after added to the cells. Further
dilutions of MEL were done with medium containing 0.2% (0.5%)
ethanol, and cells of the control group were suspended in medium
containing 0.2% (0.5%) ethanol. Therefore, all experimental groups
were exposed to the same amount of ethanol.
2.2. Determination of ROS formation in resting Jurkat cells
Formation of ROS was monitored using the oxidation sensitive dye
dihydrorhodamine 123 (DHR, Molecular Probes, Eugene, OR, USA),
which is the uncharged and non-£uorescent reduction product of the
cationic £uorescent dye rhodamine 123. Jurkat cells (2U106 cells/ml)
were incubated in RPMI in the presence of 2 WM DHR for 10 min at
37‡C. After washing, cells were resuspended in RPMI (106/ml) and
left untreated or incubated with various concentrations of MEL. At
the indicated intervals, rhodamine £uorescence was analyzed at 488
nm/525 nm (excitation/emission wavelength) using a FACScan cyto-
£uorometer (BD).
2.3. Determination of hydrogen peroxide
Since antioxidants may interact with cell culture media to generate
hydrogen peroxide [19,20], we determined hydrogen peroxide forma-
tion in RPMI1640 medium after addition of up to 2 mM MEL by
oxygen measurement in the presence of 1000 U/ml catalase using a
CLARK electrode in a thermostatted, stirred setup (Oxygraph, Anton
Paar, Graz, Austria). As a positive control, hydrogen peroxide (250
WM) was used.
2.4. Modulation and determination of intracellular glutathione (GSH)
After 24 h incubation of Jurkat cells (1U106 cells/ml) with various
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(1; 2.5; 10; 25; 100; 250 WM) concentrations of buthionine-sulfoxi-
mine (BSO), an inhibitor of intracellular GSH synthesis [13], cells
were washed twice in PBS and either stained with DHR according
to the above-mentioned protocol or used for determination of cellular
GSH concentration by the method described by Tietze [21] using a
commercially available microtiter plate assay (Dojindo Laboratories,
Japan). This assay was performed according to the manufacturer’s
instructions.
2.5. Determination of anti-fas-induced intracellular ROS formation and
cell death
Fas-induced programmed cell death was induced using the anti-fas
monoclonal antibody (mAb) CH-11 (Immunotech, Vienna, Austria)
[22]. Since active mitochondria are necessary for determination of
ROS formation with DHR, but programmed cell death is associated
with dysregulation of mitochondrial functions [23], hydroethidium
(HE), which is the oxidation sensitive reduction product of the
DNA binding dye ethidium, was used to assess ROS formation in
Jurkat cells undergoing fas-induced apoptosis. A protocol was used
according to Zamzami et al. [23] with slight modi¢cations: Brie£y,
Jurkat cells (2U106 cells/ml) were incubated in RPMI in the presence
of 2 WM HE for 10 min at 37‡C. After washing, cells were resus-
pended in RPMI (2.5U105/ml) and incubated with 100 ng/ml anti-
fas mAb CH-11 and various concentrations of MEL or glutathione-
ethylester (EGSH), which is a membrane-permeable form of GSH.
After 6 h, ethidium £uorescence was analyzed at 488 nm/600 nm
(excitation/emission wavelength) with the FACScan cyto£uorometer.
The percentage of cells undergoing apoptosis was determined using
annexin V-FITC (Pharmingen, San Diego, USA) binding and propi-
dium iodide (PI) staining, as previously described by Vermes et al.
[24]. Jurkat cells (2.5U105 cells/ml) were simultaneously incubated
with the anti-fas mAb (100 ng/ml) and various concentrations of
MEL, EGSH and trolox (TX), a water-soluble analogue of K-toco-
pherol. After 4 h cells were washed twice with ice-cold HEPES bu¡er
(10 mM HEPES/NaOH; 140 mM NaCl; 2.5 mM CaCl2 ; pH 7.4), and
the pellet was incubated with 2 Wl annexin V-FITC (1 mg/ml) and 10
Wl PI (50 Wg/ml) for 15 min at room temperature according to the
manufacturer’s instructions. The percentage of annexin V-FITC pos-
itive and PI negative cells was analyzed in the FACScan at an emis-
sion wavelength of 525 nm and 600 nm, respectively.
In a second approach, Jurkat cells were preincubated either with
MEL, TX, EGSH alone, or MEL plus TX, or MEL plus EGSH for
4 h. After thorough washing to remove the drugs, cells were treated
with anti-fas mAb (100 ng/ml) for an additional 4 h. Analysis of the
percentage of apoptotic cells was done as described above.
2.6. Statistical analysis
Using the SigmaStat 2.03 software package a repeated measures
ANOVA followed by a Tukey post-hoc analysis was calculated.
3. Results
3.1. Melatonin exerts prooxidant activity in resting Jurkat cells
In contrast to TX, which decreased intracellular rhodamine
£uorescence in resting Jurkat cells loaded with DHR (see Fig.
1B), micro- to millimolar concentrations of MEL enhanced it
in a dose- and time-dependent manner (see Fig. 1). In order to
exclude hydrogen peroxide formation in RPMI cell culture
medium, which has been shown for some antioxidants
[19,20], we measured hydrogen peroxide formation after
MEL addition as described in Section 2 in a cell-free system:
no hydrogen peroxide formation was detected (data not
shown). To exclude a possible selenium de¢ciency in long-
time cultured Jurkat cells to be responsible for the observed
prooxidant activity of MEL, Jurkat cells were preincubated
for 48 h in full medium containing 1 nm to 1 WM sodium
selenite, which did not change the results (data not shown).
Since indoleamines in general are known to in£uence the cel-
lular redox state [6,25], we investigated whether this prooxi-
dant e¡ect is speci¢c for MEL. In contrast to MEL, N-ace-
tylserotonin (NAS), which is the immediate precursor of
MEL, slightly but signi¢cantly decreased intracellular ROS
formation (data not shown), indicating that this prooxidant
e¡ect might be speci¢c for MEL.
Fig. 1. A: Increased intracellular ROS formation in Jurkat cells
after MEL treatment. Jurkat cells (2U106 cells/ml) were loaded with
2 WM DHR for 10 min at 37‡C. After washing with PBS, cells were
resuspended in RPMI (1U106/ml) and incubated with the indicated
concentrations of MEL. After the indicated time periods, rhodamine
£uorescence was analyzed using a Becton-Dickinson FACScan. 10
WM, 100 WM and 1 mM MEL led to a dose- and time-dependent
increase in intracellular ROS formation (P6 0.001 vs. controls at
each time point except 10 WM MEL after 30 min (not signi¢cant)
and 60 min (P6 0.05)). 1 WM MEL di¡ered signi¢cantly vs. con-
trols after 90, 120 and 150 min (P6 0.05). Data represent mean þ
S.E.M. of triplicates (n = 5). B: Rhodamine £uorescence (FL1) histo-
gram of MEL-treated and TX-treated Jurkat cells. While after 120
min of incubation TX decreased intracellular rhodamine £uores-
cence (dotted line) compared to controls (gray area), MEL increased
it (thick line). FL1 denotes rhodamine £uorescence.
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As shown in Fig. 2, TX was able to completely neutralize
MEL-induced ROS in Jurkat cells. Furthermore, preincuba-
tion of Jurkat cells with various concentrations of BSO, which
inhibits intracellular GSH synthesis [13], showed that the
prooxidant e¡ect of MEL is dependent on intracellular
GSH: the lower the cellular GSH concentration, the more
pronounced the prooxidant activity of MEL (Fig. 3). These
results corroborate that the observed increase in intracellular
rhodamine £uorescence is indeed due to a prooxidant cellular
activity of MEL.
3.2. MEL promotes fas-induced cell death
In order to assess the functional relevance of these ¢ndings,
we determined the e¡ect of MEL on fas-induced cell death in
Jurkat cells : As outlined in Table 1, EGSH was able to de-
crease the percentage of cells undergoing apoptosis in a dose-
dependent manner, which is in good agreement with results of
Williams et al. [12]. This was accompanied by an attenuation
of fas-induced intracellular ROS formation, as assessed using
the oxidation sensitive dye HE (see Table 1). In contrast,
MEL dose dependently enhanced the percentage of cells
undergoing fas-induced apoptosis and increased fas-induced
intracellular ROS formation. Without anti-fas mAb incuba-
tion neither MEL nor EGSH in£uenced the percentage of
annexin V binding cells.
Preincubation of Jurkat cells with MEL increased their sus-
ceptibility to fas-induced apoptosis (Fig. 4). Concomitant ad-
dition of TX as well as of EGSH abolished the e¡ect of MEL.
Interestingly, in contrast to EGSH, preincubation with TX
alone had no in£uence on the percentage of cells undergoing
fas-induced cell death, again suggesting that only thiol-con-
taining antioxidants, like EGSH, can modulate fas-induced
apoptosis [12]. Furthermore, this ¢nding suggests the involve-
ment of di¡erent ROS in fas activation and MEL-induced
intracellular oxidation processes.
4. Discussion
Our results clearly demonstrate a prooxidant cellular activ-
ity of MEL in Jurkat cells. MEL-induced ROS formation was
more pronounced in GSH-depleted cells and was counteracted
by TX. Among indoleamines, this prooxidant e¡ect might be
speci¢c for MEL, since N-acetylserotonin, which is the imme-
diate precursor of MEL and has also been described to exert
antioxidant properties [6], decreased intracellular ROS forma-
tion in our experimental setup.
These results con£ict with reports of antioxidant properties
of MEL in lymphocytes and macrophages [6,26^28]. How-
ever, Barsacchi et al. [29] showed that micromolar concentra-
tions of MEL exerted prooxidant e¡ects in human erythro-
cytes exposed to oxidative stress. These results were con¢rmed
recently by Medina-Navarro et al. [30], who reported proox-
idant properties of MEL in the in vitro interaction with singlet
oxygen. Di¡erences in the redox state and the susceptibility to
oxidant-induced changes in cell functions among di¡erent cell
types [31^33] most likely explain the con£icting results. This
Fig. 2. Reversal of MEL-induced intracellular ROS formation by
addition of TX. After loading with DHR, Jurkat cells were incu-
bated with/without 1 mM MEL. After 2 h 1 mM TX was added.
Addition of TX counteracted MEL-induced intracellular ROS for-
mation (P6 0.001). Data represent mean þ S.E.M. of triplicates of
one experiment out of three giving identical results.
Fig. 3. Correlation between intracellular GSH content and prooxi-
dant activity of MEL in Jurkat cells. After incubation with various
BSO concentrations (1^250 WM) for 24 h, Jurkat cells were either
loaded with DHR, exposed to MEL (1 mM) for 2 h and analyzed
for their rhodamine £uorescence, or their intracellular GSH concen-
tration was determined as described in Section 2. A highly signi¢-
cant negative correlation between intracellular GSH content (ex-
pressed in WM per 106 cells) and extent of prooxidant activity of
MEL was found. Data represent results from two independent ex-
periments, each done in duplicate (mean þ S.E.M. for the di¡erent
BSO concentrations indicated).
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notion is supported by the fact that ascorbic acid also in-
creased DHR oxidation in our Jurkat cell model (data not
shown). Ascorbic acid is known to exhibit antioxidant as
well as prooxidant properties both in vitro [33^36] and in
vivo [37,38].
Functional consequences of the prooxidant e¡ect of MEL
in Jurkat cells became obvious by the promotion of fas-in-
duced cell death. In human-activated peripheral blood T-cells
as well as in Jurkat cells, fas-induced apoptosis was shown to
be preceded by an increase in intracellular ROS formation
[15], and thiol-based antioxidants, such as GSH and N-acetyl-
cysteine, as well as inhibition of GSH synthesis by BSO, in-
£uenced fas-mediated cell death [12,13]. Pre- or coincubation
with MEL, which both lead to an intracellular prooxidant
state, thus may render the cells more susceptible to stimuli
of cell death, as has recently been shown to be responsible
for increased human T-cell leukemia virus-I (HTLV-I) tax-
mediated apoptosis in Jurkat cells [39]. Increased intracellular
ROS formation may also modulate the expression of the fas
receptor, since antioxidants can down-regulate fas receptor
expression on the surface of lymphocytes [40], and oxidants,
such as hydrogen peroxide, have been shown to increase fas
receptor expression in cultured human endothelial cells [41].
Concerning the in£uence of MEL on programmed cell
death, most data are available from experiments using neuro-
nal cells: While some groups reported protection against
programmed cell death in neuronal cells and cell lines by anti-
oxidant activity of MEL [42^45], Harms et al. recently dem-
onstrated that micro- to millimolar concentrations of MEL
are protective against necrotic cell death but can exaggerate
cell damage in resting primary neuronal cultures as well as
after induction of apoptosis [46]. In malignant cells, such as
the human breast cancer cell line MCF-7, micromolar concen-
trations of MEL have recently been reported to induce apo-
ptosis [47]. Furthermore, MEL was reported to enhance pro-
grammed cell death in a murine colon cancer model in vivo
[48]. The respective mechanisms for these apoptosis-promot-
ing e¡ects are unknown so far.
To summarize our presented data show that MEL can ex-
hibit strong prooxidant activity in Jurkat cells, which leads to
the promotion of fas-induced cell death. Therefore, MEL may
be a modulator of the cellular redox status in both ways, and
is not necessarily protecting against oxidative hazard. The
premises determining pro- or antioxidant e¡ects of melatonin
in cellular systems as well as the underlying mechanisms of
action have to be clari¢ed in further studies.
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Table 1
In£uence of MEL and EGSH on fas-induced cell death and its correlation to enhanced intracellular ROS formation in Jurkat cells
Treatment Percent cells undergoing apoptosis Intracellular ROS concentration
Controls 5.35 þ 0.50 42.5 þ 0.71
+Anti-fas mAb 22.11 þ 0.80 59.09 þ 0.29
MEL EGSH MEL EGSH
0.01 mM 22.34 þ 0.34 ND ND ND
0.1 mM 24.62 þ 0.18 ND 63.51 þ 0.78*** ND
0.5 mM 30.80 þ 0.48*** 21.73 þ 0.03 ND ND
1 mM 37.28 þ 0.24*** 19.73 þ 0.40* 65.97 þ 0.48*** 56.28 þ 0.33*
2.5 mM 43.60 þ 1.63*** 17.85 þ 0.18** 68.51 þ 0.77*** 55.56 þ 0.48**
5 mM ND 12.34 þ 0.04*** ND 50.26 þ 0.23***
*P6 0.05 vs. anti-fas mAb; **P6 0.01 vs. anti-fas mAb; ***P6 0.001 vs. anti-fas mAb; ND denotes not determined.
Jurkat cells (2.5U105/ml) were incubated with the indicated concentrations of MEL and EGSH in the presence of 100 ng/ml anti-fas mAb.
After 4 h, cells were washed twice with ice-cold HEPES bu¡er and the pellet was incubated with 2 Wl annexin V-FITC (1 mg/ml) and 10 Wl PI
(50 Wg/ml) for 15 min at room temperature. The percentages of annexin V positive/PI negative cells were analyzed using a Becton-Dickinson
FACScan. Concomitantly, Jurkat cells (2U106 cells/ml) were loaded with 2 WM HE for 10 min at 37‡C. After washing with PBS, cells were re-
suspended in RPMI/10% FCS (2.5U105/ml), and incubated with the indicated concentrations of MEL and EGSH in the presence of 100 ng/ml
anti-fas mAb. After 6 h, ethidium £uorescence was analyzed using a Becton-Dickinson FACScan. Data represent mean þ S.E.M. of triplicates
(n = 3).
Fig. 4. Reversal of MEL-induced enhancement of fas-mediated cell
death in Jurkat cells by TX and EGSH. Jurkat cells (2.5U105/ml)
were incubated with MEL alone, TX alone, EGSH alone, or MEL
and TX, or MEL and EGSH. 4 h later, cells were washed thor-
oughly to remove the drugs, resuspended in RPMI/10% FCS, and
incubated with 100 ng/ml anti-fas mAb. After a total of 8 h, the
percentage of apoptotic cells was determined. Data represent
mean þ S.E.M., n = 3, each done in triplicate.
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